Nancy Cox, MD
Internal Medicine · Wrens, GANPI 1811191638
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 226 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Novo Nordisk at 32.8% of the total. Reporting peaked in 2020 at $681 and has fallen 50.5% since, to $337 in 2025.
Across 226 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$705
- AstraZeneca$329
- Lilly USA, LLC$197
- Sanofi-aventis U.S. LLC$154
- Bayer$142
- plus $746 from 16 others
What the payments were for
- Food & beverage$3,367100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 77 | $1,108 |
| AbbVie(2 entities) | 61 | $705 |
| AstraZeneca | 14 | $329 |
| Lilly USA, LLC | 12 | $197 |
| Sanofi-aventis U.S. LLC | 8 | $154 |
| Bayer | 8 | $142 |
| GSK | 9 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $106 |
| Boehringer Ingelheim | 6 | $99 |
| Pfizer | 5 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $66 |
| Amgen | 3 | $48 |
| Merck | 2 | $36 |
| Globus Medical | 1 | $33 |
| Beckman Coulter, Inc. | 1 | $29 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $27 |
| Grifols USA, LLC | 1 | $19 |
| Vital Connect, Inc | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Novartis | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$3,382 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 179 | $243,629 |
| JardianceEmpagliflozin | 125 | $154,059 |
| EliquisApixaban | 74 | $82,754 |
| MounjaroTirzepatide | 45 | $64,744 |
| LinzessLinaclotide | 59 | $58,982 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $58,635 |
| FarxigaDapagliflozin Propanediol | 60 | $57,959 |
| RybelsusSemaglutide | 32 | $55,198 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $33,656 |
| JanuviaSitagliptin Phosphate | 32 | $29,886 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $27,523 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $19,906 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $17,980 |
| EntrestoSacubitril/Valsartan | 16 | $15,962 |
| TrulicityDulaglutide | 11 | $14,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,108 | $298,827211 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $99 | $159,554137 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix, Arexvy | $124 | $118,133214 claims |
| PfizerEliquis | $75 | $82,75474 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $329 | $80,002100 claims |
| Lilly USA, LLCMounjaro, Trulicity | $197 | $79,19756 claims |
| AbbVieLinzess | $705 | $58,98259 claims |
| MerckJanuvia | $36 | $29,88632 claims |
| NovartisEntresto | $18 | $15,96216 claims |
| Sanofi-aventis U.S. LLCLantus | $154 | $2,22017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Wrens
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.